{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:14:18Z","timestamp":1780373658096,"version":"3.54.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022426","name":"National Indian Health Board","doi-asserted-by":"publisher","award":["HD094378"],"award-info":[{"award-number":["HD094378"]}],"id":[{"id":"10.13039\/100022426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022426","name":"National Indian Health Board","doi-asserted-by":"publisher","award":["ES028615"],"award-info":[{"award-number":["ES028615"]}],"id":[{"id":"10.13039\/100022426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022426","name":"National Indian Health Board","doi-asserted-by":"publisher","award":["MD007602"],"award-info":[{"award-number":["MD007602"]}],"id":[{"id":"10.13039\/100022426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022426","name":"National Indian Health Board","doi-asserted-by":"publisher","award":["HD106285"],"award-info":[{"award-number":["HD106285"]}],"id":[{"id":"10.13039\/100022426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s43032-024-01608-6","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T16:01:42Z","timestamp":1718035302000},"page":"103-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting Bromodomain-Containing Protein 9 in Human Uterine Fibroid Cells"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-8946","authenticated-orcid":false,"given":"Qiwei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Falahati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azad","family":"Khosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Vafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"4","key":"1608_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1210\/endrev\/bnab039","volume":"43","author":"Q Yang","year":"2022","unstructured":"Yang Q, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2022;43(4):678\u2013719.","journal-title":"Endocr Rev"},{"issue":"14","key":"1608_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMra1209993","volume":"369","author":"SE Bulun","year":"2013","unstructured":"Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344\u201355.","journal-title":"N Engl J Med"},{"key":"1608_CR3","doi-asserted-by":"publisher","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","volume":"2","author":"EA Stewart","year":"2016","unstructured":"Stewart EA, et al. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1608_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1055\/s-0037-1607295","volume":"35","author":"RM Whynott","year":"2017","unstructured":"Whynott RM, Vaught KCC, Segars JH. The effect of uterine fibroids on infertility: a systematic review. Semin Reprod Med. 2017;35(6):523\u201332.","journal-title":"Semin Reprod Med"},{"key":"1608_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"1608_CR6","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.jmb.2016.11.020","volume":"429","author":"AK Jain","year":"2017","unstructured":"Jain AK, Barton MC. Bromodomain histone readers and cancer. J Mol Biol. 2017;429(13):2003\u201310.","journal-title":"J Mol Biol"},{"issue":"5","key":"1608_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00109-011-0837-0","volume":"90","author":"RM Rodriguez","year":"2012","unstructured":"Rodriguez RM, et al. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med (Berl). 2012;90(5):587\u201395.","journal-title":"J Mol Med (Berl)"},{"key":"1608_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.phrs.2017.11.015","volume":"129","author":"JM Sahni","year":"2018","unstructured":"Sahni JM, Keri RA. Targeting bromodomain and extraterminal proteins in breast cancer. Pharmacol Res. 2018;129:156\u201376.","journal-title":"Pharmacol Res"},{"issue":"5","key":"1608_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.fertnstert.2018.02.120","volume":"109","author":"Q Yang","year":"2018","unstructured":"Yang Q, Al-Hendy A. Non-coding RNAs: an important regulatory mechanism in pathogenesis of uterine fibroids. Fertil Steril. 2018;109(5):802\u20133.","journal-title":"Fertil Steril"},{"issue":"1","key":"1608_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.fertnstert.2020.07.024","volume":"115","author":"TD Chuang","year":"2021","unstructured":"Chuang TD, Rehan A, Khorram O. Functional role of the long noncoding RNA X-inactive specific transcript in leiomyoma pathogenesis. Fertil Steril. 2021;115(1):238\u201347.","journal-title":"Fertil Steril"},{"issue":"12","key":"1608_CR11","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1016\/j.celrep.2019.11.077","volume":"29","author":"JW George","year":"2019","unstructured":"George JW, et al. Integrated epigenome, exome, and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. Cell Rep. 2019;29(12):4069-4085 e6.","journal-title":"Cell Rep"},{"issue":"1","key":"1608_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41467-020-14701-6","volume":"11","author":"MB Moyo","year":"2020","unstructured":"Moyo MB, Parker JB, Chakravarti D. Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas. Nat Commun. 2020;11(1):1019.","journal-title":"Nat Commun"},{"issue":"23","key":"1608_CR13","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/cells11233801","volume":"11","author":"Q Yang","year":"2022","unstructured":"Yang Q, et al. Targeting class I histone deacetylases in human uterine leiomyosarcoma. Cells. 2022;11(23):3801.","journal-title":"Cells."},{"issue":"5968","key":"1608_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1126\/science.1179689","volume":"327","author":"S Zhao","year":"2010","unstructured":"Zhao S, et al. Regulation of cellular metabolism by protein lysine acetylation. Science. 2010;327(5968):1000\u20134.","journal-title":"Science"},{"issue":"4","key":"1608_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrm.2016.143","volume":"18","author":"T Fujisawa","year":"2017","unstructured":"Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18(4):246\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1608_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","volume":"106","author":"E Ferri","year":"2016","unstructured":"Ferri E, Petosa C, McKenna CE. Bromodomains: structure, function and pharmacology of inhibition. Biochem Pharmacol. 2016;106:1\u201318.","journal-title":"Biochem Pharmacol"},{"issue":"41","key":"1608_CR17","doi-asserted-by":"publisher","first-page":"12476","DOI":"10.1002\/anie.201705516","volume":"56","author":"M Hugle","year":"2017","unstructured":"Hugle M, et al. Beyond the BET family: targeting CBP\/p300 with 4-Acyl pyrroles. Angew Chem Int Ed Engl. 2017;56(41):12476\u201380.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"1608_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cmdc.201800738","volume":"14","author":"MA Clegg","year":"2019","unstructured":"Clegg MA, et al. Advancements in the development of non-BET bromodomain chemical probes. ChemMedChem. 2019;14(4):362\u201385.","journal-title":"ChemMedChem"},{"key":"1608_CR19","doi-asserted-by":"crossref","unstructured":"Vichaikul S, et al. Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight. 2022;7(9):e150871.","DOI":"10.1172\/jci.insight.150871"},{"key":"1608_CR20","doi-asserted-by":"publisher","first-page":"105804","DOI":"10.1016\/j.phrs.2021.105804","volume":"172","author":"Q Wang","year":"2021","unstructured":"Wang Q, et al. Selectively targeting individual bromodomain: drug discovery and molecular mechanisms. Pharmacol Res. 2021;172:105804.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1608_CR21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","volume":"26","author":"N Zaware","year":"2019","unstructured":"Zaware N, Zhou MM. Bromodomain biology and drug discovery. Nat Struct Mol Biol. 2019;26(10):870\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"1608_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592\u2013601.","journal-title":"Nat Genet"},{"key":"1608_CR23","doi-asserted-by":"publisher","first-page":"123428","DOI":"10.1016\/j.ijbiomac.2023.123428","volume":"230","author":"MM Ali","year":"2023","unstructured":"Ali MM, et al. Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): its therapeutic potential and selective inhibition. Int J Biol Macromol. 2023;230:123428.","journal-title":"Int J Biol Macromol"},{"issue":"21","key":"1608_CR24","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.3390\/ijms232113513","volume":"23","author":"MM Ali","year":"2022","unstructured":"Ali MM, et al. Identification of selective BRD9 inhibitor via integrated computational approach. Int J Mol Sci. 2022;23(21):13513.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"1608_CR25","doi-asserted-by":"publisher","first-page":"16330","DOI":"10.1038\/s41598-020-73500-7","volume":"10","author":"SG Park","year":"2020","unstructured":"Park SG, et al. Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells. Sci Rep. 2020;10(1):16330.","journal-title":"Sci Rep"},{"issue":"7","key":"1608_CR26","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1158\/1541-7786.MCR-18-1121","volume":"17","author":"SM Bevill","year":"2019","unstructured":"Bevill SM, et al. GSK2801, a BAZ2\/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Mol Cancer Res. 2019;17(7):1503\u201318.","journal-title":"Mol Cancer Res"},{"issue":"10","key":"1608_CR27","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1021\/acs.jmedchem.5b01865","volume":"59","author":"LJ Martin","year":"2016","unstructured":"Martin LJ, et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J Med Chem. 2016;59(10):4462\u201375.","journal-title":"J Med Chem"},{"key":"1608_CR28","doi-asserted-by":"crossref","unstructured":"Mason LD, et al. The BRD9\/7 inhibitor TP-472 blocks melanoma tumor growth by suppressing ECM-mediated oncogenic signaling and inducing apoptosis. Cancers (Basel). 2021;13(21):5516.","DOI":"10.3390\/cancers13215516"},{"issue":"2","key":"1608_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/ijms25020905","volume":"25","author":"Q Yang","year":"2024","unstructured":"Yang Q, et al. Bromodomain-containing protein 9 regulates signaling pathways and reprograms the epigenome in immortalized human uterine fibroid cells. Int J Mol Sci. 2024;25(2):905.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"1608_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/01.LAB.0000017499.51216.3E","volume":"82","author":"SA Carney","year":"2002","unstructured":"Carney SA, et al. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest. 2002;82(6):719\u201328.","journal-title":"Lab Invest"},{"issue":"6","key":"1608_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cpr.12076","volume":"46","author":"Q Yang","year":"2013","unstructured":"Yang Q, et al. Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells. Cell Prolif. 2013;46(6):654\u201364.","journal-title":"Cell Prolif"},{"issue":"12","key":"1608_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"1608_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"2","key":"1608_CR34","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law CW, et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.","journal-title":"Genome Biol"},{"issue":"W1","key":"1608_CR35","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1608_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1095\/biolreprod.115.134924","volume":"94","author":"Q Yang","year":"2016","unstructured":"Yang Q, et al. The polycomb group protein EZH2 impairs DNA damage repair gene expression in human uterine fibroids. Biol Reprod. 2016;94(3):69.","journal-title":"Biol Reprod."},{"issue":"13","key":"1608_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1101\/gad.262766.115","volume":"29","author":"Y Yue","year":"2015","unstructured":"Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015;29(13):1343\u201355.","journal-title":"Genes Dev"},{"issue":"2","key":"1608_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93\u20135.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"1608_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tig.2012.11.003","volume":"29","author":"G Jia","year":"2013","unstructured":"Jia G, Fu Y, He C. Reversible RNA adenosine methylation in biological regulation. Trends Genet. 2013;29(2):108\u201315.","journal-title":"Trends Genet"},{"issue":"7835","key":"1608_CR40","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-020-2854-z","volume":"587","author":"CPM Scheitl","year":"2020","unstructured":"Scheitl CPM, et al. Site-specific RNA methylation by a methyltransferase ribozyme. Nature. 2020;587(7835):663\u20137.","journal-title":"Nature"},{"key":"1608_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-020-00203-6","volume":"8","author":"H Shen","year":"2020","unstructured":"Shen H, et al. The emerging roles of N6-methyladenosine RNA methylation in human cancers. Biomark Res. 2020;8:24.","journal-title":"Biomark Res"},{"issue":"6","key":"1608_CR42","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.3390\/ijms24065778","volume":"24","author":"Q Yang","year":"2023","unstructured":"Yang Q, Al-Hendy A. Update on the role and regulatory mechanism of extracellular matrix in the pathogenesis of uterine fibroids. Int J Mol Sci. 2023;24(6):5778.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"1608_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2012.11.006","volume":"23","author":"SA Bert","year":"2013","unstructured":"Bert SA, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 2013;23(1):9\u201322.","journal-title":"Cancer Cell"},{"issue":"1","key":"1608_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/cells10010053","volume":"10","author":"N Garcia","year":"2020","unstructured":"Garcia N, et al. Targeting hedgehog pathway and DNA methyltransferases in uterine leiomyosarcoma cells. Cells. 2020;10(1):53.","journal-title":"Cells."},{"issue":"14","key":"1608_CR45","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2174\/0929867328666211108105214","volume":"29","author":"S Zaib","year":"2022","unstructured":"Zaib S, Rana N, Khan I. Histone modifications and their role in epigenetics of cancer. Curr Med Chem. 2022;29(14):2399\u2013411.","journal-title":"Curr Med Chem"},{"issue":"1","key":"1608_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13148-021-01107-4","volume":"13","author":"S Keyvani-Ghamsari","year":"2021","unstructured":"Keyvani-Ghamsari S, et al. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenetics. 2021;13(1):120.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"1608_CR47","doi-asserted-by":"publisher","first-page":"e1517","DOI":"10.1210\/clinem\/dgz227","volume":"105","author":"M Ali","year":"2020","unstructured":"Ali M, et al. Activation of beta-catenin signaling and its crosstalk with estrogen and histone deacetylases in human uterine fibroids. J Clin Endocrinol Metab. 2020;105(4):e1517\u201335.","journal-title":"J Clin Endocrinol Metab."},{"key":"1608_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fphar.2016.00040","volume":"7","author":"Q Yang","year":"2016","unstructured":"Yang Q, Diamond MP, Al-Hendy A. Early life adverse environmental exposures increase the risk of uterine fibroid development: role of epigenetic regulation. Front Pharmacol. 2016;7:40.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1608_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PPO.0b013e31803c74cf","volume":"13","author":"DS Schrump","year":"2007","unstructured":"Schrump DS, Hong JA, Nguyen DM. Utilization of chromatin remodeling agents for lung cancer therapy. Cancer J. 2007;13(1):56\u201364.","journal-title":"Cancer J"},{"issue":"12","key":"1608_CR50","doi-asserted-by":"publisher","first-page":"a018663","DOI":"10.1101\/cshperspect.a018663","volume":"6","author":"J Qi","year":"2014","unstructured":"Qi J. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Cold Spring Harb Perspect Biol. 2014;6(12):a018663.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"1608_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1874467212666190215112915","volume":"12","author":"J Kaur","year":"2019","unstructured":"Kaur J, Daoud A, Eblen ST. Targeting chromatin remodeling for cancer therapy. Curr Mol Pharmacol. 2019;12(3):215\u201329.","journal-title":"Curr Mol Pharmacol"},{"issue":"16","key":"1608_CR52","doi-asserted-by":"publisher","first-page":"E1490","DOI":"10.1073\/pnas.1219992110","volume":"110","author":"L Magnani","year":"2013","unstructured":"Magnani L, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2013;110(16):E1490\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1608_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","volume":"18","author":"AG Cochran","year":"2019","unstructured":"Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019;18(8):609\u201328.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1608_CR54","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1039\/C6MD00373G","volume":"7","author":"M Moustakim","year":"2016","unstructured":"Moustakim M, et al. Chemical probes and inhibitors of bromodomains outside the BET family. Medchemcomm. 2016;7(12):2246\u201364.","journal-title":"Medchemcomm"},{"issue":"6","key":"1608_CR55","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1021\/acs.jmedchem.9b01980","volume":"63","author":"RM Karim","year":"2020","unstructured":"Karim RM, et al. Structural basis of inhibitor selectivity in the BRD7\/9 subfamily of bromodomains. J Med Chem. 2020;63(6):3227\u201337.","journal-title":"J Med Chem"},{"issue":"21","key":"1608_CR56","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1002\/anie.201501394","volume":"54","author":"PG Clark","year":"2015","unstructured":"Clark PG, et al. LP99: discovery and synthesis of the first selective BRD7\/9 bromodomain inhibitor. Angew Chem Int Ed Engl. 2015;54(21):6217\u201321.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"1608_CR57","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1021\/acs.jmedchem.5b00256","volume":"59","author":"NH Theodoulou","year":"2016","unstructured":"Theodoulou NH, et al. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. J Med Chem. 2016;59(4):1425\u201339.","journal-title":"J Med Chem"},{"issue":"7","key":"1608_CR58","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/ijms18071537","volume":"18","author":"KF Kr\u00e4mer","year":"2017","unstructured":"Kr\u00e4mer KF, et al. BRD9 inhibition, alone or in combination with cytostatic compounds as a therapeutic approach in rhabdoid tumors. Int J Mol Sci. 2017;18(7):1537.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"1608_CR59","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/s41467-020-16443-x","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, et al. The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair. Nat Commun. 2020;11(1):2639.","journal-title":"Nat Commun"},{"issue":"7","key":"1608_CR60","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.21037\/tcr-21-42","volume":"10","author":"L Zhou","year":"2021","unstructured":"Zhou L, et al. Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells. Transl Cancer Res. 2021;10(7):3364\u201372.","journal-title":"Transl Cancer Res"},{"issue":"2","key":"1608_CR61","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/cam4.4954","volume":"12","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, et al. BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma. Cancer Med. 2023;12(2):1572\u201387.","journal-title":"Cancer Med"},{"key":"1608_CR62","doi-asserted-by":"crossref","unstructured":"Yang Q, et al. The functional role and regulatory mechanism of bromodomain-containing protein 9 in human uterine leiomyosarcoma. Cells. 2022;11(14):2160.","DOI":"10.3390\/cells11142160"},{"key":"1608_CR63","doi-asserted-by":"crossref","unstructured":"Molteni E, et al. GSK2801 reverses paclitaxel resistance in anaplastic thyroid cancer cell lines through MYCN downregulation. Int J Mol Sci. 2023;24(6):5993.","DOI":"10.3390\/ijms24065993"},{"issue":"11","key":"1608_CR64","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41419-021-04186-6","volume":"12","author":"J Mu","year":"2021","unstructured":"Mu J, et al. BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors. Cell Death Dis. 2021;12(11):962.","journal-title":"Cell Death Dis"},{"issue":"15","key":"1608_CR65","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.molcel.2023.06.024","volume":"83","author":"J Zhang","year":"2023","unstructured":"Zhang J, et al. A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023;83(15):2692-2708 e7.","journal-title":"Mol Cell"},{"issue":"6633","key":"1608_CR66","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1126\/science.abj9090","volume":"379","author":"PC He","year":"2023","unstructured":"He PC, et al. Exon architecture controls mRNA m(6)A suppression and gene expression. Science. 2023;379(6633):677\u201382.","journal-title":"Science"},{"issue":"6596","key":"1608_CR67","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1126\/science.abe9582","volume":"376","author":"J Wei","year":"2022","unstructured":"Wei J, et al. FTO mediates LINE1 m(6)A demethylation and chromatin regulation in mESCs and mouse development. Science. 2022;376(6596):968\u201373.","journal-title":"Science"},{"key":"1608_CR68","doi-asserted-by":"publisher","first-page":"110731","DOI":"10.1016\/j.biopha.2020.110731","volume":"131","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, et al. Principles of RNA methylation and their implications for biology and medicine. Biomed Pharmacother. 2020;131:110731.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1608_CR69","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41419-023-05866-1","volume":"14","author":"S Wan","year":"2023","unstructured":"Wan S, et al. METTL3-dependent m(6)A methylation facilitates uterine receptivity and female fertility via balancing estrogen and progesterone signaling. Cell Death Dis. 2023;14(6):349.","journal-title":"Cell Death Dis"},{"key":"1608_CR70","doi-asserted-by":"crossref","unstructured":"Yang Q, Al-Hendy A. The functional role and regulatory mechanism of FTO m(6)A RNA demethylase in human uterine leiomyosarcoma. Int J Mol Sci. 2023;24(9):7957.","DOI":"10.3390\/ijms24097957"},{"issue":"1","key":"1608_CR71","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1186\/s12885-022-10490-x","volume":"22","author":"F Fang","year":"2022","unstructured":"Fang F, et al. m(6)A RNA methylation regulator-based signature for prognostic prediction and its potential immunological role in uterine corpus endometrial carcinoma. BMC Cancer. 2022;22(1):1364.","journal-title":"BMC Cancer"},{"issue":"164","key":"1608_CR72","first-page":"111","volume":"31","author":"Y Feng","year":"2021","unstructured":"Feng Y, et al. Gene signatures and prognostic value of m6A RNA methylation regulators in uterine corpus endometrial carcinoma. Discov Med. 2021;31(164):111\u201320.","journal-title":"Discov Med"},{"issue":"21","key":"1608_CR73","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.7150\/jca.46386","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma. J Cancer. 2020;11(21):6390\u2013401.","journal-title":"J Cancer"},{"issue":"2","key":"1608_CR74","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.tig.2021.06.014","volume":"38","author":"RL Kan","year":"2022","unstructured":"Kan RL, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 2022;38(2):182\u201393.","journal-title":"Trends Genet"},{"issue":"6053","key":"1608_CR75","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.1208930","volume":"334","author":"N Makinen","year":"2011","unstructured":"Makinen N, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252\u20135.","journal-title":"Science"},{"issue":"3","key":"1608_CR76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/gcc.22029","volume":"52","author":"DN Markowski","year":"2013","unstructured":"Markowski DN, et al. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors. Genes Chromosomes Cancer. 2013;52(3):297\u2013304.","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"1608_CR77","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1210\/jc.2018-00863","volume":"103","author":"MJ Park","year":"2018","unstructured":"Park MJ, et al. Mediator kinase disruption in MED12-mutant uterine fibroids from hispanic women of South Texas. J Clin Endocrinol Metab. 2018;103(11):4283\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1608_CR78","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1172\/JCI81534","volume":"125","author":"P Mittal","year":"2015","unstructured":"Mittal P, et al. Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest. 2015;125(8):3280\u20134.","journal-title":"J Clin Invest"},{"issue":"21","key":"1608_CR79","doi-asserted-by":"publisher","first-page":"34762","DOI":"10.18632\/oncotarget.16711","volume":"8","author":"J Bloch","year":"2017","unstructured":"Bloch J, et al. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth. Oncotarget. 2017;8(21):34762\u201372.","journal-title":"Oncotarget"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-024-01608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-024-01608-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-024-01608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T17:56:37Z","timestamp":1736790997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-024-01608-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1608"],"URL":"https:\/\/doi.org\/10.1007\/s43032-024-01608-6","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"The manuscript was reviewed and approved by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}